Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Gastrointestinal CancerFurther Publications

Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020

★ 3 Recommended and commented by Alexander Meisel, Faculty Member

healthbook TIMES Oncology Hematology

Corresponding author: Dr Alexander Siebenhüner Senior Consultant in Medical Oncology Cantonal Hospital Schaffhausen Schaffhausen, Switzerland

SPECIAL REPORT

Gastrointestinal CancerFurther Publications

Why Liquid Biopsy for GI Tumor Treatment Matters

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Alexander Meisel, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer.

Ohashi K, Ninomiya K, Yoshioka H, Bessho A, Shibayama T, Aoe K, Ishikawa N, Kozuki T, Kawai H, Kuyama S, Miyoshi S, Fujitaka K, Obata H, Tsubata Y, Awaya Y, Inoue M, Inoue K, Horita N, Yanai H, Hotta K, Kiura K

doi: 10.1016/j.lungcan.2020.09.024.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Alexander Meisel, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Ohashi K, Ninomiya K, Yoshioka H, Bessho A, Shibayama T, Aoe K, Ishikawa N, Kozuki T, Kawai H, Kuyama S, Miyoshi S, Fujitaka K, Obata H, Tsubata Y, Awaya Y, Inoue M, Inoue K, Horita N, Yanai H, Hotta K, Kiura K

doi: 10.1016/j.lungcan.2020.09.024

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lung Cancer

Park K, Özgüroğlu M, Vansteenkiste J, Spigel D, Yang JC, Bajars M, Ruisi M, Manitz J, Barlesi F

doi: 10.1016/j.lungcan.2021.01.026

Central Nervous System TumorsLung, Respiratory and Thoracic Cancer

Significant Survival Benefit of Atezolizumab in Second-Line NSCLC Regardless of PD-L1 Status (The OAK Study)

Breast Cancer

Breast Cancer Treatment in the Era of Precision Medicine

1Breast Cancer Center, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland

Breast Cancer

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial

JAMA Oncol.

Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP

doi: 10.1001/jamaoncol.

Related content

Recent Developments in Metastatic Breast Cancer

Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020

Why Liquid Biopsy for GI Tumor Treatment Matters

Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

Significant Survival Benefit of Atezolizumab in Second-Line NSCLC Regardless of PD-L1 Status (The OAK Study)

Breast Cancer Treatment in the Era of Precision Medicine

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial